Screener / SEC EDGAR /CIK 0000939767 /10-K filed Feb 10, 2026, compared with Feb 11, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Exelixis, Inc. EXEL

Compare with peers Embed
Cash returned and share count

No buyback or stock pay figures in its 10-K data yet

XBRL, 10-K

Where the cash came from and where it went

FY2025, from the cash flow statement in the 10-K, added up

Operating cash flowOther, netCapital spendingBuybacksAdded to cash Operating cash flow: $884.3M Operating cash flow $884.3M Other, net: $336.8M Other, net $336.8M Capital spending: $8.4M Capital spending $8.4M Buybacks: $947.5M Buybacks $947.5M Added to cash: $265.1M Added to cash $265.1M

Came from

Operating cash flow $884.3M
Other, net
investments bought and sold, other financing and investing lines, and exchange rates
$336.8M

Each number is a line of the cash flow statement as the company tagged it. "Other, net" is what those lines do not cover (investments bought and sold, other financing and investing lines, and exchange rates); Tickdelta does not estimate it.

Where the operating cash went, year by year

FY2016 to FY2025 · cash flow statements, 10-K XBRL

10 years
Operating cash, added up $4.2B 10 fiscal years, FY2016 to FY2025
Reinvested 6% capital spending and acquisitions, as a share of that cash
Returned to owners 51% buybacks and dividends, as a share of that cash
Debt repaid $185.8M gross repayments added up; debt that was refinanced counts each time
Fiscal yearOperating cashCapital spendingBuybacksDebt repaid
Jan 2, 2026 $884.3M $8.4M$947.5M-
Jan 3, 2025 $700.0M $28.4M$652.0M-
Dec 29, 2023 $333.3M $40.5M$550.4M-
Dec 30, 2022 $362.6M $27.7M--
Dec 31, 2021 $400.8M $54.2M--
Jan 1, 2021 $209.0M $30.3M--
Jan 3, 2020 $527.0M $12.8M--
Dec 28, 2018 $415.7M $33.3M--
Dec 29, 2017 $165.6M $21.1M-$185.8M
Dec 31, 2016 $206.3M $1.7M--
Added up$4.2B $258.6M
6% of operating cash
$2.1B
51% of operating cash
$185.8M
4% of operating cash

Each bar is one fiscal year; its colours add up to what the cash flow statement says the company spent on each line, and the line across it is that year's operating cash flow. Spending above the line was paid from new debt, shares sold or cash on hand. A bar part links to the 10-K it comes from. A line the company did not report is left out, not estimated, so the shares are of operating cash only and can add up to more or less than 100%. Debt repaid is the gross amount, so refinanced debt is counted each time it is repaid. A reading aid, not a grade: Tickdelta does not say whether a split was good. Banks and insurers are left out.

Buybacks, dividends and share count

Year by year · XBRL, each 10-K

No buyback or share count data in the 10-K XBRL.

Buybacks month by month, and what is left to buy

Share buybacks · 10-Q, Part II Item 2, latest 4 quarters

Still open to buy $347.9M under the programme, end of Oct 2026
Latest month 1,627,000 shares Oct 2026, average $57.62

“In May 2026, our Board of Directors authorized the repurchase of up to $750.0 million of our outstanding common stock before December 31, 2027 (the May 2026 SRP).”

10-Q, Part II Item 2

“As of September 30, 2026, approximately $347.9 million remained available for future stock repurchases before December 31, 2027.”

10-Q, Part II Item 2
MonthShares boughtAverage price
Oct 2026 1,627,000 $57.62
Aug 2026 1,453,000 $53.71
Jul 2026 1,401,000 $55.78
Jul 2026 1,705,000 $52.59
May 2026 3,091,000 $44.85
May 2026 1,717,000 $48.52
Apr 2026 3,994,000 $41.74
Feb 2026 3,022,000 $43.70
Jan 2026 3,005,000 $43.95
Aug 2025 1,970,000 $42.64
Aug 2025 405,000 $37.08

Shares and average price are the numbers in the 10-Q table, row by row; "shares × price" is our multiplication of the two. A row with a price of "-" is an accelerated repurchase paid up front, where the 10-Q does not give a price yet. A 10-Q that counts shares in millions gives a rounded number, shown as "about". Shares withheld for employees' taxes are not in this table. A month that no 10-Q table gives, or that this page could not read with confidence, is not shown.

What it paid for each share it bought back

Price paid · 10-K, statement of shareholders' equity

Cheapest year $38.40 fiscal year to Jan 2, 2026
Dearest year $38.40 fiscal year to Jan 2, 2026
Average over these years $38.40 $1.2B spent

What EXEL paid on average for each share it bought back, each fiscal year: dollars spent divided by shares bought, both from the 10-K.

Fiscal year toShares boughtSpentAverage price
Jan 2, 2026 30.20M$1.2B $38.40

Shares and dollars from the statement of shareholders' equity (the cash flow line also counts shares withheld for taxes, so it is not used). Share counts filed before a stock split are put on today's count. A year where the 10-K does not tag both numbers is left out.

What the 10-Ks show for each CEO's years

Each CEO's years · the CEO of each fiscal year as named in the proxy's pay versus performance table

Dr. Morrissey

FY2025 · 1 year in the table
Operating cash flow
$884.3M
Capital spending
$8.4M
Buybacks
$947.5M
Stock-based pay
$113.0M
Diluted shares since FY2024
-4.8%
Revenue since FY2024
+7%
CEO pay (reported)
$33.2M
The proxy that names the CEO

Sources

The cash flow statement, dividends per share and diluted share count in each 10-K's XBRL; Part II Item 2 of each 10-Q for monthly buybacks; offering prospectuses (S-3, 424B) for new shares; Form D data sets for private raises.

Also

CEO pay: what the CEO was paid over the same years.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/EXEL/export.csv") into a cell.

Next:CEO pay
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.